Transcatheter aortic valve implantation has been established as an alternative treatment option for patients with severe aortic stenosis presenting with prohibitively high surgical risk or ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Patients who underwent transcatheter aortic ... open heart surgery in patients who are eligible for either procedure. The study was funded by JenaValve, maker of the Trilogy valve.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

In younger patients, Surgical Aortic Valve Replacement (SAVR) remains the treatment of choice. However, the ACC/AHA (American College of Cardiology/American Heart Association) guidelines suggest ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...